September 18, 2023 02:36 PM EDTUpdated September 19, 05:33 PM
Pharma
Marketing

As­traZeneca rolls up car­dio­vas­cu­lar, re­nal and meta­bol­ic in­ter­con­nec­tions in film and dig­i­tal ef­fort

Beth Snyder Bulik

Senior Editor

As­traZeneca is putting its car­dio­vas­cu­lar, re­nal and meta­bol­ic (CVRM) port­fo­lio in the spot­light with a short film and dig­i­tal cam­paign. The two-minute

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times